Answers are grounded in this paper and cite their sources.
Introduction FES encodes a non‐receptor tyrosine kinase with context‐dependent functions in cancer; however, its cross‐cancer genomic landscape, immune microenvironmental relevance, and therapeutic implications remain incompletely defined. We therefore characterized FES across cancers and validated its functional and therapeutic relevance experimentally. Methods We integrated transcriptomic, genomic, clinical, pharmacogenomic, immunogenomic, and spatial transcriptomic datasets from TCGA, GTEx, GEO, GDSC, the Connectivity Map, and public spatial transcriptomic resources. Experimental validation was performed in gastric cancer cell lines HGC‐27 and AGS using shRNA‐mediated FES knockdown, qRT‐PCR, cell viability and Transwell migration assays under four conditions (sh‐NC, sh‐FES, imatinib, and sh‐FES plus imatinib), followed by validation in a nude mouse xenograft model. Results FES showed marked cancer type‐specific dysregulation, being downregulated in several epithelial malignancies but upregulated in kidney renal clear cell carcinoma and stomach adenocarcinoma, while overall mutation frequency remained low. FES showed strong diagnostic discrimination in multiple cancers and was associated with unfavorable survival in lower‐grade glioma, glioblastoma, colon adenocarcinoma, and stomach adenocarcinoma. Systems-level analyses linked high FES expression to epithelial–mesenchymal transition, angiogenesis, inflammatory response, and IL6/JAK/STAT3 signaling. FES was broadly and positively correlated with chemokines, immune checkpoint molecules, MHC‐related genes, and infiltration of macrophages, dendritic cells, fibroblasts, and endothelial cells. Spatial transcriptomic analysis localized FES expression to immune‐ and stromal‐enriched tumor regions, and pharmacogenomic analyses nominated imatinib as a candidate compound capable of reversing the FES-related expression signature. Experimentally, FES knockdown reduced FES mRNA expression, cell viability, migratory capacity, and xenograft growth. Imatinib produced additional inhibitory effects, and the combined intervention consistently showed the strongest suppression in vitro and in vivo . Discussion These findings suggest that FES expression is associated with immune‐inflammatory features across cancer types and highlight its potential therapeutic relevance in gastric cancer. The convergence of pan‐cancer multi‐omics evidence with cellular and animal validation supports further investigation of FES for tumor stratification and therapeutic targeting, particularly in gastric cancer.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: